SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics S.p.A. effective December 17, 2021. Napo Therapeutics is a European specialty drug development and marketing company based in Milan, Italy.
"Our mission at Napo Therapeutics is to provide access to Jaguar Health's proprietary first-in-class plant-based medicine crofelemer in Europe to address significant rare disease indications – and our initial focus is on clinical development and future registration in Europe of crofelemer for two debilitating orphan target indications: Short bowel syndrome with intestinal failure (SBS-IF) and congenital diarrheal disorders (CDD). We believe Napo Therapeutics will support and facilitate expanded and accelerated patient access to a novel therapy. The name-change to Napo Therapeutics reflects our focus on rare diseases and orphan-drugs," commented Massimo Mineo, General Manager of Napo Therapeutics.
Crofelemer is a novel, plant-based oral chloride ion channel modulator that boasts a unique anti-secretory mechanism of action, acting locally in the gastrointestinal tract to modulate and normalize the patient's waterflow.
"Normal functioning of the small intestine is crucial to optimize a patient's absorption of fluids and nutrients to support life. Crofelemer's ability to regulate ion channels in the gut normalizes the salt and water balance in the small intestine, which may lead to better absorption of fluids and nutrients in those living with SBS-IF," Mr. Mineo said.
Napo Therapeutics is pursuing the accelerated conditional marketing authorization pathway from the European Medicines Agency (EMA) for crofelemer for short bowel syndrome (SBS) under orphan-drug designation (ODD).
As announced December 13, 2021, the EMA has granted ODD for crofelemer for the SBS indication in the European Union following review of the ODD application Napo Therapeutics submitted to the EMA this past September. Following this decision from the EMA, Napo Therapeutics is initiating efforts to plan and commence a pivotal clinical trial of crofelemer in both adult and pediatric SBS patients in support of the company's key focus on pursuing the EMA's accelerated conditional marketing authorization pathway in Europe for this rare disease. Crofelemer previously received ODD in the U.S. from the U.S. Food and Drug Administration for SBS.
About Short Bowel Syndrome (SBS)
SBS is a complex condition characterized by severe malabsorption of fluids and nutrients due to surgical resection of bowel segments, congenital anomalies, or disease-associated loss of absorption. For SBS patients who endure the catastrophic loss of their bowel, the resulting excessive intestinal fluid output and lifelong restriction and adjustment of oral intake of food and liquids leads to the requirement to receive intravenous fluids for most of every day (parenteral nutrition). This challenges their ability to carry out activities of daily living, or to attend school or work, and has a significant impact on their daily quality of life. Furthermore, lifelong parenteral nutrition leads to potentially life-threatening complications like sepsis and organ failure. SBS affects approximately 10,000 to 20,000 people in the U.S.1, according to the Crohn's & Colitis Foundation, and it is estimated that the population of SBS patients in Europe is approximately the same size.2 Despite limited treatment options, the global SBS market exceeded $568 million in 2019 and is expected to reach $4.6 billion by 2027, according to a report by Vision Research Reports.
"We believe that crofelemer's first-in-class mechanism of action may potentially benefit and change the lives of people suffering from this devastating rare disease," added Mr. Mineo.
CDD refers to a group of inherited enteropathies with a typical onset early in life. Infants with CDD experience frequent chronic diarrhea of sufficient severity to require parenteral nutrition.
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo Therapeutics S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Napo Therapeutics S.p.A., the majority owned Italian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit www.napoeu.com.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the belief that Napo Therapeutics will support and facilitate expanded and accelerated patient access to a novel therapy, the expectation that crofelemer's ability to regulate ion channels in the gut may lead to better absorption of fluids and nutrients in those living with SBS-IF, the expectation that Napo Therapeutics will commence a pivotal clinical trial of crofelemer in both adult and pediatric SBS patients, the expectation that the global SBS market may reach $4.6 billion by 2027, and the belief that crofelemer's first-in-class mechanism of action may potentially benefit and change the lives of people suffering SBS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Jaguar Health, Inc.
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
Every investor knows that the path toward profits lies in buying low and selling high. That’s a basic precept of any economic trading system. The trick, however, is recognizing when the stock is low enough to buy in. The prime moment to buy is when the stock hits bottom; that will maximize returns when the share price starts to rise again. There are a multitude of possible clues investors can use to find the price bottom; today, we’ll be looking at insider buying trends. Insiders – the corporate
(Bloomberg) — The head of India’s main medical research agency said there were “major safety concerns” over Merck & Co.’s Covid-19 drug that may impede its addition to the country’s viral treatment list.Even though India’s drug regulator last week approved Merck’s molnupiravir for emergency use, Balram Bhargava, the director general of the state-funded Indian Council of Medical Research, said the government has yet to decide on whether to recommend molnupiravir, even as coronavirus infection ra
Clinical-stage biotech Aligos Therapeutics (NASDAQ: ALGS) had some bad news to report on Thursday. This was the issue with Aligos on Thursday; in the morning the company divulged that it is halting the further development of its experimental drug ALG-010133, which targets chronic hepatitis B (CHB). The decision was made based on data from a phase 1 study of the drug, which demonstrated that with ALG-010133, "at the projected efficacious dose … there is no meaningful [hepatitis B surface antigen] reduction" in patients with the disease.
Sutro stock collapsed Thursday — and was among the biggest biotech stock dives — after its ovarian cancer study disappointed investors.
A Main Line pharmaceutical company has, for the second time, submitted an application seeking emergency use authorization for its experimental Covid-19 therapy from the Food and Drug Administration NRx Pharmaceuticals (NASDAQ: NRXP) of Radnor is seeking the authorization for the use of its new drug candidate, Zyesami, in critical patients with Covid-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir. The company initially sought emergency use approval for Zyesami in a broader group of Covid patients last year, but that application was rejected by the FDA.
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more. Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of Greater Boston life sciences and health care happenings.
The Omicron variant has quickly taken over the world, resulting in rising COVID cases, breakthrough infections, and reinfections. This new version of the virus has already pushed the U.S. to report more than one million new daily COVID cases on Jan. 3, and virus experts expect its surge to continue throughout the month, if not longer. More than 95 percent of cases in the country are estimated to be caused by Omicron, and every time the virus evolves, so can the illness it produces. According to
It has been a rough 12 months for Humanigen (HGEN), with shares down by 80%. Investors will be hoping 2022 will provide more joy; the company’s prospective Covid-19 treatment could go some way to changing sentiment around this beaten down name. On Wednesday, Humanigen announced it had reached its enrollment target in the Phase 2/3 ACTIV-5/BET-B trial assessing Covid-19 treatment lenzilumab in COVID-19 patients. There are now more than 400 patients in the primary analysis population – patients wi
The Cambridge drugmaker is just one of scores of Massachusetts-based biotech and health care companies that are scheduled to present at the conference.
Employees of a Starbucks store in upstate New York who voted to unionize last month walked off the job Wednesday, saying they lacked the staff and resources to work safely amid surging COVID-19 cases.
Kansas City is facing a COVID testing frenzy, but when should you actually take a test? Does it matter what kind of test? We found some answers.
At-home testing options are limited in availability, delayed in delivery time, or entirely out of stock depending on the brand and retailer as the Omicron variant surges in the U.S.
With so many fake COVID face masks being sold online, it's important to pay attention to a few details when you order.
One of the Louisville area's largest employers has delayed its return to office indefinitely and is requiring employees and contractors who work outside of the home to receive a booster shot. Humana Inc. (NYSE: HUM) most recently planned to have its employees return to the office on Jan. 14. The latest move was made in response to the surge of the omicron variant, according to Mark Taylor, Humana's director of corporate and financial communications.
Experts weigh in as some retailers raise prices on at-home rapid antigen tests.
From loss of smell and taste to shortness of breath, we're well aware of the standard symptoms of COVID. But the virus has steadily evolved from its original form, and with it, so have the symptoms it might cause. A new variant called Omicron is estimated to make up more than 95 percent of COVID infection in the U.S. right now, according to the Centers for Disease Control and Prevention (CDC). Doctors are now warning that the signs of this version of the virus may be a little different from the
Dr. Payal Patel, infectious diseases physician at University of Michigan, joins Yahoo Finance to discuss the CDC’s isolation guidelines, plus how schools are dealing with the Omicron surge.
Experts are keeping a wary eye on yet another COVID-19 variant, this one with 46 mutations. It was detected in France and showed up in a traveler who recently arrived from a three-day stay in Cameroon, French researchers said in a pre-print study published on medRxiv, which means it has not yet been peer-reviewed. While researchers were monitoring the strain to ascertain how infectious it is …
The anti-vax senator from Kentucky described the Covid-19 variant as "nature's vaccine" in an interview with Fox News on Wednesday
Ignoring the pandemic isn’t right, but neither is overhyping the risk. The majority that is vaccinated but living life needs support. [Opinion]